On June 5, 2013, the U.S. Food and Drug Administration (FDA) approved lenalidomide capsules (Revlimid®, Celgene Corporation), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

The approval was based a single-arm, multicenter clinical trial enrolling 134 patients with MCL who have relapsed after or were refractory to bortezomib or a bortezomib-containing regimen. All 134 patients received prior treatment with bortezomib, and 60% were documented to have disease refractory to bortezomib therapy. Patients received a median of four prior therapies for MCL. The median age was 67 years, 81% were male, 96% were Caucasian, and 61% had MCL for at least three years.

The efficacy endpoints were overall response rate (ORR) and duration of response (DOR). The ORR was defined as the proportion of patients whose best response was complete response (CR), complete response unconfirmed (CRu), or partial response (PR). In the 133 patients who were evaluable for efficacy, the ORR was 26% (95% CI: 18.4, 33.9). CR or CRu was achieved by 9 patients (7%) and 25 patients (19%) achieved a PR. The median DOR for the 34 patients who achieved a CR, CRu, or PR was 16.6 months (95% CI: 7.7, 26.7). 

Safety data was evaluated in 134 patients who received at least one dose of lenalidomide. The median duration of therapy was 95 days (range = 1–1,002), and 78 (58%) of patients received three or more cycles of therapy. Seventy-six patients (57%) underwent at least one dose interruption, 51 patients (38%) underwent at least one dose reduction, and 26 patients (19%) discontinued treatment, all because of adverse events. 

The most common (≥ 15%) grade 1–4 adverse reactions included neutropenia, thrombocytopenia, fatigue, anemia, diarrhea, nausea, cough, pyrexia, rash, dyspnea, pruritis, constipation, peripheral edema, and leukopenia. The most common (≥ 5%) grade 3–4 adverse reactions were neutropenia, thrombocytopenia, anemia, pneumonia, leukopenia, fatigue, febrile neutropenia, dyspnea, and diarrhea.

The recommended dose and schedule for lenalidomide is 25 mg orally once daily on days 1–21 of repeated 28-day cycles. Lenalidomide should be taken at about the same time each day, either with or without food.

This supplemental application also included the approval of a new 20 mg capsule strength. 

Full prescribing information is available. 

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing an online form, by faxing (800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (800-FDA-1088).

In collaboration with the FDA and as a service to our members, ONS will provide updates on recent FDA approvals and other important FDA actions (e.g., updated safety information, new prescribing information) pertaining to therapies for patients with cancer. This will allow the agency to inform oncologists and professionals in oncology-related fields in a timely manner. Included in the FDA updates will be a link to the product label or to other sites for additional relevant clinical information. In supplying this information, ONS does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.